Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study

Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study Publisher Pubmed

Ghadami L¹ ; Hasibi M² ; Asadollahiamin A³ ; Asanjarani B² ; Farahmand M⁴ ; Abdollahi H⁵

Show Affiliations

1. Department of Health Care Management, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Internal Ward, Amiralam Hospital, Tehran University Medical Sciences, Tehran, Iran
3. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Medical Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Anesthesthia and Critical Care, Amiralam Hospital, Tehran University Medical Sciences, Tehran, Iran

Source: Microbial Pathogenesis Published:2022

Abstract

Convalescent plasma (CP) therapy has been suggested as a treatment for emerging viral diseases. Moreover, many studies have been conducted to evaluate the efficacy of COVID-19 CP therapy, with some of them indicating that CP may be a promising treatment for the disease. However, the evidence for CP therapy's effectiveness in severe COVID-19 cases is limited. So, this study aimed to assess the probable effects of CP therapy in patients diagnosed with severe COVID-19. The study was designed as a single-arm, retrospective cohort of patients with severe COVID. Demographic data, laboratory test reports, and convalescent plasma transfusion doses were collected from medical records for patients before and after convalescent plasma transfusion. The clinical outcomes were hospital discharge and death. Also, laboratory parameters considered secondary outcomes. After CP therapy, some symptoms improved, especially in patients under 55 years old, as follows. Respiratory function was significantly enhanced after convalescent plasma transfusion, and the inflammatory biomarkers' values decreased significantly (p < 0.05). Moreover, the estimated median of partial thromboplastin time (PTT) and Prothrombin time (PT) in patients did not change after CP therapy (p > 0.05). Regarding COVID-19 mortality, a strong association was found between older ages and death (p < 0.001). Also, CP transfusion in the early days of admission was effective in treatment outcomes (p = 0.023). Other characteristics, including sex, blood group, number of CP transfusions, and preexisting conditions, did not significantly correlate with mortality. In conclusion, this study demonstrates the effectiveness of CP therapy in patients under the age of 55. Despite some improvement, we could not say that they were entirely due to the CP treatment. More extensive randomized clinical trials that cover different stages of the disease are needed. © 2022

Related Docs

View other Related Docs

1. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)

2. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)

3. The Immune System As a Target for Therapy of Sars-Cov-2: A Systematic Review of the Current Immunotherapies for Covid-19, Life Sciences (2020)

4. Convalescent Plasma Against Covid-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases, Microorganisms (2020)

5. Recent Advances in Antibody-Based Immunotherapy Strategies for Covid-19, Journal of Cellular Biochemistry (2021)

6. Convalescent Plasma Therapy for Covid-19: Lessons From Sars-Cov, Mers-Cov, and H1n1 Infection, Acta Medica Indonesiana (2021)

7. Case Fatality Rate of Covid-19: A Systematic Review and Meta-Analysis, Journal of Preventive Medicine and Hygiene (2021)

8. Non-Steroidal Anti-Inflammatory Drugs in Management of Covid-19; a Systematic Review on Current Evidence, International Journal of Clinical Practice (2020)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (18)

Mohammadreza Salehi (6)

Style	Citing Format
MLA	Ghadami L, et al.. "Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study." Microbial Pathogenesis, vol. 165, no. , 2022, pp. -.
APA	Ghadami L, Hasibi M, Asadollahiamin A, Asanjarani B, Farahmand M, Abdollahi H (2022). Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study. Microbial Pathogenesis, 165(), -.
Chicago	Ghadami L, Hasibi M, Asadollahiamin A, Asanjarani B, Farahmand M, Abdollahi H. "Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study." Microbial Pathogenesis 165, no. (2022): -.
Harvard	Ghadami L et al. (2022) 'Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study', Microbial Pathogenesis, 165(), pp. -.
Vancouver	Ghadami L, Hasibi M, Asadollahiamin A, Asanjarani B, Farahmand M, Abdollahi H. Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study. Microbial Pathogenesis. 2022;165():-.
BibTex	@article{ author = {Ghadami L and Hasibi M and Asadollahiamin A and Asanjarani B and Farahmand M and Abdollahi H}, title = {Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study}, journal = {Microbial Pathogenesis}, volume = {165}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Ghadami L AU - Hasibi M AU - Asadollahiamin A AU - Asanjarani B AU - Farahmand M AU - Abdollahi H TI - Convalescent Plasma Therapy in Patients With Severe Covid-19, a Single-Arm, Retrospective Study JO - Microbial Pathogenesis VL - 165 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract